Skip to main content
Clinical Trials/NCT02252094
NCT02252094
Terminated
N/A

Ultra-protective Pulmonary Ventilation Supported by Low Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) and Prone Positioning for ARDS; a Pilot Study.

National University Health System, Singapore2 sites in 1 country8 target enrollmentMay 22, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Respiratory Distress Syndrome, Adult
Sponsor
National University Health System, Singapore
Enrollment
8
Locations
2
Primary Endpoint
Plateau Pressure
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

This study evaluates the use of ultra-protective ventilation, where very low ventilation volumes are used, in patients with severe acute respiratory distress syndrome (ARDS) meeting criteria to nurse in the prone position. Half the patients will receive ultra-protective ventilation support by extracorporeal carbon dioxide removal, while the other half will receive conventional lung protective ventilation.

Detailed Description

Current best practices for management of severe ARDS include lung protective ventilation and nursing in the prone position. However, the best lung protective strategy is not currently established and using smaller ventilation volumes than standard lung protective ventilation suggest lung recovery is improved. Application of smaller ventilation volumes requires extracorporeal carbon dioxide removal, using a device similar to a dialysis to remove carbon dioxide directly from the blood. One such device in the Prismalung, it removes blood through a catheter, much like a dialysis catheter, pumps it through a gas exchange cartridge which removes carbon dioxide. The gas exchange cartridge functions in a similar way to a dialysis filter, except it allow gases to pass through, unlike dialysis filters which allow passage of fluid and small molecules.

Registry
clinicaltrials.gov
Start Date
May 22, 2017
End Date
May 31, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National University Health System, Singapore
Responsible Party
Principal Investigator
Principal Investigator

Matthew COVE

Matthew COVE

National University Health System, Singapore

Eligibility Criteria

Inclusion Criteria

  • Admitted to MICU with respiratory failure and intubated
  • ARDS criteria per Berlin definition
  • PaO2:FiO2 ratio ≤ 200 mmHg for \> 6 hours with FiO2 ≥0.5
  • Expected to require mechanical ventilation for \>48 hours
  • Reversible disease

Exclusion Criteria

  • Anticoagulation contraindicated
  • Proven HIT
  • Unable to obtain central venous access
  • Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication for ECMO
  • Home oxygen use
  • Severe COPD
  • Interstitial lung disease
  • \> 7 days of mechanical ventilation
  • Immunocompromised patient (bone marrow, untreated HIV, PJP)
  • Advanced malignancy with life expectancy ≤ 6months

Outcomes

Primary Outcomes

Plateau Pressure

Time Frame: Duration of ventilation for severe ARDS, expected average time 10 days

Ability to achieve a plateau pressure of \</=25 cmH20 in the intervention arm

Secondary Outcomes

  • Length of hospital stay(Duration of patient stay in hospital)
  • Cardiac Imaging(One data set per patient during first 72 hours)
  • Ability to successfully prone(Duration of ICU stay)
  • Enrolment rates(First 48 hours)
  • Mortality(Monitored for 3 months)
  • Extracorporeal carbon dioxide removal related complications(Duration of severe ARDS, expected average time frame 10 days)
  • Ventilator free days(28 days)
  • Ventilation parameters(Duration of mechanical ventilation)
  • Ventilator associated pneumonia rates(Duration of ICU stay)
  • Number of patient meeting proning criteria in each group(Duration of ICU stay)
  • Lung recruitability(Duration of ICU stay)
  • Length of stay in ICU stay(Duration of patient stay in ICU, expected average stay 2 weeks)
  • Biomarkers of Pulmonary Inflammation(Day 0, 4 and 7)
  • All severe adverse events(Duration of ICU stay (anticipate average stay 1-2 weeks))
  • Incidence of dialysis in ICU, and ability to successfully initiate(Duration of ICU stay)
  • Incidence of referrals for ECMO(Duration of ICU stay)
  • Rate and reasons for declining consent to study participation(First 48 hours)
  • Barotrauma complications(Duration of ICU stay)

Study Sites (2)

Loading locations...

Similar Trials